Work

PA-322 Open-Label, Single-Arm Phase Ib/II Study of Immune Combination Therapy with Belantamab Mafodotin and Elotuzumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Year: 2026

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)03685-2

Authors: Sabrina L. Browning, Fangyong Li, Terri L. Parker, Noffar Bar, Catherine Wei, Tara Anderson, Erica Stevens, Jennifer VanOudenhove, Martin Matthews, Elan Gorshein, Jason Haldas, Ashita Talsani, Stuart Seropian, Kert Sabbath, Stephanie Halene, Natalia Neparidze

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7213890124

Cites:

Cited by:

Related to: 10